future of glp-1 drugs Market Trends and Global Forecasts Report 2025: A $157.5 Bn Market by 2035 GLP-1 Medications: Everything You Need
Description
Gender difference in cardiovascular outcomes with SGLT-2 inhibitors and GLP-1 receptor agonist in type 2 diabetes: A systematic review and meta-analysis of cardio-vascular outcome trials
Limitations Despite these strengths, several limitations must be acknowledged
AstraZeneca UK Limited sponsored data collection and analysis for this study
Pfizer has since filed two lawsuits to block Novos acquisition
And the researchers did not observe the liver toxicity that had plagued some earlier small molecule GLP-1 drugs
